Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01895777 · ClinicalTrials.gov registry record · Phase 3

Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

A Phase 3 study, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 3
Development phase
267
Enrollment target

NCT01895777: Completed Phase 3 study, sponsored by Boehringer Ingelheim.

NCT01895777 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 267 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01895777, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 3
Development phase
267 participants
Enrollment target

Study Summary

The main objectives of this large phase IIb/III paediatric study are to assess the efficacy and safety of dabigatran etexilate relative to standard of care and to document the appropriateness of the proposed dabigatran etexilate dosing algorithm for use in patients from birth to less than 18 years of age.

Primary Outcome

The primary endpoint was the combined endpoint of the proportions of patients with: * Complete thrombus resolution * Freedom from recurrent VTE * Freedom from mortality related to VTE. The events outlined in the above combined primary endpoint were assessed by radiologists or other such qualified clinicians using an appropriate method such as ultrasound, echocardiography, venography, or CT scan, based on the location of the thrombus and the test used to perform the baseline assessment. The pri

Interventions

  • DRUG standard of care
  • DRUG dabigatran etexilate

Trial Details

FieldValue
Enrollment Target 267 participants
Start Date 2013-09-25
Est. Completion 2019-11-14
Phase Phase 3
Boehringer Ingelheim

515 total trials

What the finished NCT01895777 record still lists

NCT01895777 is an interventional study that assigns participants to a tested intervention. The registered 267 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).

The record links to 0 conditions, and to 2 interventions - of which standard of care is the first listed.

NCT01895777 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01895777 about?

NCT01895777 is a clinical study titled "Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)". The main objectives of this large phase IIb/III paediatric study are to assess the efficacy and safety of dabigatran etexilate relative to standard of care and to document the appropriateness of the proposed dabigatran etexilate dosing algorithm for use in patients from birth to less than 18 years o...

What is the current status of trial NCT01895777?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 267 participants. The study started on 2013-09-25. Estimated completion is 2019-11-14.

What interventions are being tested in trial NCT01895777?

The interventions under investigation include: standard of care (DRUG), dabigatran etexilate (DRUG).

Who is sponsoring clinical trial NCT01895777?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01895777's enrollment target sits among peer trials

267 1222nd of 2000 higher than 779 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04997109 · 267 participants · NA

    Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy

  • NCT05355701 · 267 participants · Phase 1

    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

  • NCT06203509 · 267 participants · NA

    Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness

  • NCT05000632 · 268 participants · NA

    Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01895777, the US trial registry maintained by the National Library of Medicine. NCT01895777 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.